Potter, Danielle S.
Du, Ruochen
Bohl, Stephan R.
Chow, Kin-Hoe
Ligon, Keith L. http://orcid.org/0000-0002-7733-600X
Bueno, Raphael
Letai, Anthony http://orcid.org/0000-0002-1993-9013
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (1R35CA242427)
Ludwig Institute for Cancer Research
U.S. Department of Defense (CA160891, CA160891, CA160891)
Article History
Received: 2 November 2021
Accepted: 5 May 2023
First Online: 20 May 2023
Competing interests
: A.L. discloses consulting and sponsored research agreements with AbbVie, Novartis, and AstraZeneca. He is on the scientific advisory board of Anji Onco, Flash Therapeutics, Dialectic Therapeutics, and Zentalis Therapeutics. K.L.L. discloses consulting from BMS, Integragen, and Rarecyte. D.S.P. is now employed by AstraZeneca. K.L.L. is a founder and equity holder of Travera LLC. K.L.L. has sponsored research agreements with BMS and Lilly. The following are US Patents regarding BH3 profiling, owned by Dana-Farber: 10,393,733; 9,902,759; 9,856,303; 9,540,674; 8,221,966; 7,868,133. A.L. is an inventor on patent applications US20180128813A1, US20180120297A1 held/submitted by Dana-Farber Cancer Institute that covers HTDBP. Remaining authors declare no competing interests.
: Primary MPM tumors described in the manuscript were obtained, after patients signed an informed consent approved by the Institutional Review Board (#98-063). All mice used in the manuscript were maintained within the DCFI animal facility and all experiments involving animals were conducted in accordance with the DFCI policy and animal protocol, reviewed and approved by the DFCI Institutional Animal Care and Use Committee.